ConductScience.org, home

Paper41409286

The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy.

Wang Z and 2 others. Front Immunol, 2025. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy. Papers, record 41409286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41409286

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy.
PubMed
Journal
Front Immunol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
1.14, provisional
iCite
Revised in PubMed
2025-12-20
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang ZZhihao
2Miao LLele
3Wang WWei

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunotherapy, AdoptiveMajor topic
Breast NeoplasmsMajor topic
Receptors, Chimeric AntigenMajor topic
T-LymphocytesMajor topic
Humans
Female
Tumor Microenvironment
Animals
Antigens, Neoplasm
Receptors, Antigen, T-Cell
Coping Skills

Source PubMed

Download CSV of topics

References134

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134378338Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy.Small2021https://conductscience.org/library/papers/34378338PubMed
225849134Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.Nat Med2015https://conductscience.org/library/papers/25849134PubMed
339213364Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer.Sci Adv2024https://conductscience.org/library/papers/39213364PubMed
434343496CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment.Cell2021https://conductscience.org/library/papers/34343496PubMed
540102282Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies.Med Oncol2025https://conductscience.org/library/papers/40102282PubMed
633010818Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice.Mol Ther2021https://conductscience.org/library/papers/33010818PubMed
740715608Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells.Med Oncol2025https://conductscience.org/library/papers/40715608PubMed
840072049Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy.Cells2025https://conductscience.org/library/papers/40072049PubMed
928223273PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.Clin Cancer Res2017https://conductscience.org/library/papers/28223273PubMed
1039511890Proton pump inhibitor attenuates acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis.Mol Ther2025https://conductscience.org/library/papers/39511890PubMed
1127526682Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.J Hematol Oncol2016https://conductscience.org/library/papers/27526682PubMed
1240033418Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer.Exp Hematol Oncol2025https://conductscience.org/library/papers/40033418PubMed
1334048683CAR T-cell therapy for multiple myeloma: state of the art and prospects.Lancet Haematol2021https://conductscience.org/library/papers/34048683PubMed
1440460374Spatiotemporal dynamics of tumor-CAR T-cell interaction following local administration in solid cancers.PLoS Comput Biol2025https://conductscience.org/library/papers/40460374PubMed
1530404198Receptor Tyrosine Kinase-Targeted Cancer Therapy.Int J Mol Sci2018https://conductscience.org/library/papers/30404198PubMed
1637418008CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.Cancer Immunol Immunother2023https://conductscience.org/library/papers/37418008PubMed
1740514065Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis.J Immunother Cancer2025https://conductscience.org/library/papers/40514065PubMed
1833382402STING agonist promotes CAR T cell trafficking and persistence in breast cancer.J Exp Med2021https://conductscience.org/library/papers/33382402PubMed
1938572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
2037377890Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.Cancer Res Commun2023https://conductscience.org/library/papers/37377890PubMed

See all 134 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42769774Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape.Oncol Res2026https://conductscience.org/library/papers/42769774PubMed
42527931Harnessing immunity against breast cancer: from checkpoints to cell therapies.J Transl Med2026https://conductscience.org/library/papers/42527931PubMed
42224282Multi-omics and pan-cancer analysis revealed common molecular signatures to disclose multitargeted anticancer agents through network pharmacology approach.PLoS One2026https://conductscience.org/library/papers/42224282PubMed
42214174Combined treatment of TROP‑2 targeted CAR-T and vascular disruptor CBP enhances anti‑tumor activity in triple‑negative breast cancer.Transl Oncol2026https://conductscience.org/library/papers/42214174PubMed
41976388Human-Centric Modeling in Metastatic Breast Cancer: Organoids, Organ-on-Chip Systems, and New Approach Methodologies in the Post-FDA Modernization Act 2.0 Era.Cancers (Basel)2026https://conductscience.org/library/papers/41976388PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41409286

GET https://conductscience.org/api/papers/v1/41409286/references?page=2